ABT — Abbott Laboratories Share Price
Last trade - 00:00- $227.16bn
- $233.56bn
- $41.95bn
- 96
- 29
- 89
- 83
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 24.66 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -24.34% | ||
| Dividend Yield (f) | 1.81% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.77 | ||
| Price to Tang. Book | 12.68 | ||
| Price to Free Cashflow | 35.77 | ||
| Price to Sales | 5.36 | ||
| EV to EBITDA | 23.96 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 10.28% | ||
| Return on Equity | 31.23% | ||
| Operating Margin | 16.33% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 34,608 | 43,075 | 43,653 | 40,109 | 41,950 | 44,601.06 | 48,010.41 | 5.63% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +17.68 | +61.46 | +2.12 | -16.76 | +128.07 | -34.04 | +10.23 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Abbott Laboratories is a global healthcare company. The Company is engaged in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. The Diagnostic Products segment is engaged in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment is involved in the worldwide sales of a broad line of adult and pediatric nutritional products. The Medical Devices segment includes the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care products.
Directors
- Robert Ford CHM (47)
- Robert Funck CFO (59)
- Hubert Allen EVP (55)
- Mary Moreland EVP (54)
- John Capek EVP (59)
- Lisa Earnhardt EVP (51)
- John Ginascol EVP (62)
- Andrew Lane EVP (50)
- Daniel Salvadori EVP (42)
- Andrea Wainer EVP (52)
- Gregory Ahlberg SVP (54)
- Roger Bird SVP (64)
- Charles Brynelsen SVP (64)
- Michael Dale SVP (61)
- Sammy Karam SVP (59)
- Joseph Manning SVP (52)
- Michael Pederson SVP (59)
- Christopher Scoggins SVP (51)
- Jared Watkin SVP (53)
- Alejandro Wellisch SVP (46)
- Randel Woodgrift SVP (59)
- Philip Boudreau VFN (48)
- William Osborn LED (73)
- Patricia Gonzalez DRC
- Robert Alpern IND (70)
- Roxanne Austin IND (60)
- Sally Blount IND (59)
- Michelle Kumbier IND (53)
- Darren McDew IND (60)
- Nancy Mckinstry IND (62)
- Daniel Starks IND (66)
- John Stratton IND (60)
- Glenn Tilton IND (72)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- March 6th, 1900
- Public Since
- March 1st, 1937
- No. of Shareholders
- 30,768
- No. of Employees
- 114,000
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 1,734,323,411
- Address
- 100 Abbott Park Road, Abbot Park, ABBOTT PARK, 60064-3500
- Web
- https://www.abbott.com
- Phone
- +1 2246676100
- Auditors
- Ernst & Young LLP
Latest News for ABT
Upcoming Events for ABT
Abbott Laboratories Annual Shareholders Meeting
Abbott Laboratories Annual Shareholders Meeting
Q2 2025 Abbott Laboratories Earnings Release
Q3 2025 Abbott Laboratories Earnings Release
Similar to ABT
Agilent Technologies
New York Stock Exchange
Alcon AG
New York Stock Exchange
Artivion
New York Stock Exchange
Avanos Medical
New York Stock Exchange
Avantor
New York Stock Exchange
FAQ
As of Today at 19:02 UTC, shares in Abbott Laboratories are trading at $130.98. This share price information is delayed by 15 minutes.
Shares in Abbott Laboratories last closed at $130.98 and the price had moved by +23.68% over the past 365 days. In terms of relative price strength the Abbott Laboratories share price has outperformed the S&P500 Index by +16.3% over the past year.
The overall consensus recommendation for Abbott Laboratories is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Abbott Laboratories dividend yield is 1.71% based on the trailing twelve month period.
Last year, Abbott Laboratories paid a total dividend of $2.24, and it currently has a trailing dividend yield of 1.71%.Looking ahead, the next dividend pay date is 2025-05-15.
We do not have data on when Abbott Laboratories is to next pay dividends. The historic dividend yield on Abbott Laboratories shares is currently 1.71%.
To buy shares in Abbott Laboratories you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $130.98, shares in Abbott Laboratories had a market capitalisation of $227.16bn.
Here are the trading details for Abbott Laboratories:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: ABT
Based on an overall assessment of its quality, value and momentum Abbott Laboratories is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Abbott Laboratories is $141.19. That is 7.8% above the last closing price of $130.98.
Analysts covering Abbott Laboratories currently have a consensus Earnings Per Share (EPS) forecast of $5.15 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Abbott Laboratories. Over the past six months, its share price has outperformed the S&P500 Index by +21.57%.
As of the last closing price of $130.98, shares in Abbott Laboratories were trading +10.95% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Abbott Laboratories PE ratio based on its reported earnings over the past 12 months is 24.66. The shares last closed at $130.98.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Abbott Laboratories' management team is headed by:
- Robert Ford - CHM
- Robert Funck - CFO
- Hubert Allen - EVP
- Mary Moreland - EVP
- John Capek - EVP
- Lisa Earnhardt - EVP
- John Ginascol - EVP
- Andrew Lane - EVP
- Daniel Salvadori - EVP
- Andrea Wainer - EVP
- Gregory Ahlberg - SVP
- Roger Bird - SVP
- Charles Brynelsen - SVP
- Michael Dale - SVP
- Sammy Karam - SVP
- Joseph Manning - SVP
- Michael Pederson - SVP
- Christopher Scoggins - SVP
- Jared Watkin - SVP
- Alejandro Wellisch - SVP
- Randel Woodgrift - SVP
- Philip Boudreau - VFN
- William Osborn - LED
- Patricia Gonzalez - DRC
- Robert Alpern - IND
- Roxanne Austin - IND
- Sally Blount - IND
- Michelle Kumbier - IND
- Darren McDew - IND
- Nancy Mckinstry - IND
- Daniel Starks - IND
- John Stratton - IND
- Glenn Tilton - IND